Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Meningioma 1Medulloblastoma 1

Interventions

Vincristine 8Magnetic Resonance Spectroscopy 8Cyclophosphamide 7Cisplatin 6X-Rays 5Specimen Handling 5Radiotherapy 5Phantoms, Imaging 5Irinotecan 5Carboplatin 5Temozolomide 4Radiation 4Platinum 4Nuclear Medicine Department, Hospital 4Lomustine 4palbociclib 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Etoposide 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tipifarnib 2tazemetostat 2sonidegib 2selpercatinib 2olaparib 2merphos 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Medulloblastoma × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡